Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mitopure skin serum passes safety check in 112 volunteers

NCT ID NCT07517874

Symptom relief Sponsor: Amazentis SA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a topical serum containing Mitopure causes skin irritation or allergic reactions. 112 healthy adults, half with sensitive skin, wore patches with the serum repeatedly. The goal was to see if the product is safe for skin use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mitopure (topical skin serum)
What this could lead to
If successful, this could show that Mitopure is safe for skin and may be used in future skincare products.
What could go wrong
This is a small, early safety study, not designed to prove any skin benefits. Results may not apply to people with skin conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

112 people

The number who actually took part.

Started

Apr 2026

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy males or females,18 years of age or older (50% with sensitive skin). * Completed written informed consent. * Female subject agrees to use an acceptable method of birth control (e.g. abstinence, condoms, hormonal birth control, IUD, tubal ligation, hysterectomy, bilateral oophorectomy, hysterectomy, post-menopausal for at least one year or male partner vasectomy). Exclusion Criteria: * Pregnancy or lactation. * Participation in a repeat insult patch test (RIPT) or follow-up work within the last month. * Current treatment by a physician for allergy unless physician consulted by Investigator and participation approved.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Irritation/irritant are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypersensitivity reaction disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Irritation/irritant Sensitisation

Contacts and locations

Locations

  • PCR Corp

    Manchester, M13 0AF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.